Sato, M., C. H. Turner, et al. 1998. "LY353381.HCl: A Novel Raloxifene Analog with Improved SERM Potency and Efficacy In Vivo." *The Journal of Pharmacology and Experimental Therapeutics* 287(1): 1–7.

Semmelhack, M. F., T. W. Author, et al. *J Am. Chem. Soc* 103: 6460.

Terenius, L. 1971. "The Allen-Doisy Test for Estrogens Reinvestigated." *Steroids*: 653–661.

Thompson, D. D. 1995. "Estrogen Agonists as Remedies for Prostate Cardiovascular Diseases". U.S. Pat. No. : 5,441, 986. Aug. 15, 1995.

Thompson, D. D. 1996. "Benzo-Thiophene Estrogen Agonists to Treat Prostatic Hyperplasia". U.S. Pat. No. : 5,589,482. Dec. 31, 1996.

Tietze, L.-F. and T. Eicher. 1989. *Reactions and Syntheses in the Organic Chemistry Laboratory*. Eng. University Science Books: 181.

Van de Velde, P., F. Nique, et al. 1994. "RU 58 688, a New Pure Antiestrogen Inducing a Regression of Human Mammary Carcinoma Implanted in Nude Mice." *J. Steroid Biochem. Molec. Biol.* 48(2/3): 187–196.

Wilson, T. M., et al. 1997. *Endocrinology* 138(9): 3901–3911.

Wilson, T. M., J. D. Norris, et al. 1997. "Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor In Bone." *Endocrinology* 138(9): 3901–3911.

Wilson, T. M. 1997. "Non-Steroidal Ligands for the Estrogen Receptor". U.S. Pat. No. : 5,681,835. Oct. 28, 1997.

Wilson, T. M. 1999. "Non-Steroidal Ligands for the Estrogen Receptor". U.S. Pat. No. : 5,977,219. Mar. 2, 1999.

What is claimed is:

1. A compound having a formula selected from the group consisting of:



and their pharmaceutically acceptable salts, wherein:

R_1 and R_3 are selected independently from the group consisting of optionally substituted hydroxyaryls and alkoxyaryls; R_2 is selected from the group consisting of hydrogen and optionally substituted loweralkyls and R_4 is selected from the group consisting of optionally substituted cycloalkyls.

2. The compound of claim **1**, wherein R_1 iand R_3 are selected independently from the group consisting of optionally substituted hydroxyaryls.

3. The compound of claim **1**, wherein R_1 and R_3 are selected independently from the group consisting of optionally substitutcd alkoxyaryls.

4. The compound of claim **1**, wherein at least one of R_1 and R_3 is substituted with at least one hydroxy or alkyloxy group.

5. The compound of claim **1**, wherein at least one of R_1 and R_3 is selected independently from the group consisting of optionally substituted phenyloxyloweralkyls.

6. The compound of claim **5**, wherein at least one of R_1 and R_3 is substituted with a substituent selected from the group consisting of halogen, nitro, cyano, loweralkyl, halolowerlalky, loweralkyloxy, halololoweralkyloxy, carboxy, loweralkyloxycarbonyl, aryloxycarbonyl, (cyclololoweralkyl) oxycarbonyl, aralkyloxycarbonyl, heteroaryloxycarbonyl, heteroaralkyloxycarbonyl, (heterocyclololoweralkyl) oxycarbonyl, loweralkylsulfinyl, loweralkylsulfonyl, loweralkylthio, arylthio, loweralkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy, heteroarylcarbonyloxy, heteroaralkylcarbonyloxy, (cyclololoweralkyl) carbonyloxy, alkylsulfonylamino, (heterocyclololoweralkyl) carbonyloxy, aminocarbonyl, loweraklylaminocarbolnyl, arylaminocarbonyl, aralkylaminocarbonyl, heteroarylaminocarbonyl, and heteroaralkylalminocarbonyl.

7. The compound of claim **6**, wherein at least one of R_1 and R_3 is substituted with a substituten selected fromn the group consisting of halogen, nitro, cyano, loweralkyl, halololoweralalkyl, loweralkyloxy, halolowerlakyloxy, carboxy, loweralkylthio, aminocarbonyl, and loweralkylsulfinyl.

8. The compound of claim **1**, wherein R2 is hydrogen.

9. The compound of claim **1**, wherein R2 is optionally substituted loweralkyl.

10. The compound of claim **1**, wherein at least one of R1 and R3 is substituted with at least one hydroxy or thio group.

11. The compound of claim **1**, wherein at least one of R1 and R3 is substituted with a substituent selected from the group consisting of halogen, loweralkyl, halolowerlalkyl, loweralkyloxy, halolowerlakyloxy, carboxy, loweralkyloxycarbonyl, aryloxycarbonyl, (cyclololoweralkyl) oxycarbonyl, aralkyloxycarbonyl, heteroaryloxycarbonyl, heteroaralkyloxycarbonyl, (heterocyclololoweralkyl) oxycarbonyl, loweralkylsulfinyl, loweralkylsulfinyl, loweralkylthio, arylthio, loweralkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy, heteroarylcarbonylloxy, heteroaralkylcarbonyloxy, (cyclololoweralkyl) carbonyloxy, (heterocyclololoweralkyl) carbonyloxy, aminocarbonyl, loweralkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, heteroarylaminocarbonyl, and heteroaralkylaminocarbonyl.

12. A composition for use in treating an estrogen receptor-mediated disorder in a mammal, comprising a therapeutically effective amount of a compound of claim **1** in a pharmaceutically effective carrier.

* * * * *